Heart disease remains one of the leading causes of death around the world. Millions of people suffer from heart attacks, strokes, and other serious heart problems every year.
Because of this, doctors have spent decades searching for the best ways to protect patients from dangerous blood clots that can block blood flow to the heart or brain.
For many years, aspirin has been one of the most widely used medicines for people with heart disease. Aspirin works by making blood platelets less sticky, which reduces the chance of blood clots forming inside arteries. Since clots are a major cause of heart attacks and strokes, aspirin has helped save countless lives.
Doctors often recommend aspirin to people who have already had a heart attack, undergone heart procedures such as stent placement, or who are at high risk of cardiovascular disease. Aspirin is cheap, easy to access, and has been used for decades.
However, aspirin is not perfect. One of its biggest problems is that it can increase the risk of bleeding. Because aspirin thins the blood, it can sometimes cause serious bleeding in the stomach, intestines, or even the brain. For some patients, these side effects can become dangerous and may outweigh the benefits.
This has led scientists to search for better alternatives that can prevent blood clots while causing fewer complications. Now, a new study from researchers at the Cardiocentro Ticino Foundation in Switzerland suggests that another type of blood-thinning medicine may work even better than aspirin for many people with heart disease.
The study focused on medicines called P2Y12 inhibitors. These drugs include well-known medications such as clopidogrel, prasugrel, and ticagrelor. They are already commonly used together with aspirin for a short period after a heart attack or after doctors place a stent in a blocked artery.
P2Y12 inhibitors work differently from aspirin, but they also stop platelets from clumping together and forming dangerous clots. Researchers wanted to know whether taking one of these drugs alone, instead of aspirin, could offer better long-term protection.
To answer this question, scientists studied more than 24,000 patients with heart disease. About half of the participants took aspirin, while the other half took a P2Y12 inhibitor by itself. The researchers then followed the patients for around 18 months to compare their health outcomes.
The results were impressive. People taking P2Y12 inhibitors had fewer heart attacks and strokes than those taking aspirin. Overall, the risk of major cardiovascular problems was reduced by 12% in the P2Y12 group.
Even more striking, the number of heart attacks was reduced by 23% among patients taking P2Y12 inhibitors compared to aspirin users. In heart disease treatment, even small improvements can save many lives, so this reduction is considered very important.
One of the biggest concerns with blood-thinning drugs is bleeding risk. Doctors are always careful because stronger blood thinners can sometimes increase dangerous bleeding. Surprisingly, the study found that major bleeding was not more common in people taking P2Y12 inhibitors.
In fact, serious bleeding in areas such as the stomach and brain occurred less often in the P2Y12 group compared to those taking aspirin. This finding suggests that these newer medications may not only work better but could also be safer for some patients.
The study was led by Professor Marco Valgimigli and his research team. The scientists believe their findings may eventually change the standard treatment approach for many heart disease patients.
For decades, aspirin has been considered the default long-term medicine for preventing future heart attacks and strokes. But this new research suggests that P2Y12 inhibitors could potentially replace aspirin as the first-choice treatment for many people with cardiovascular disease.
Heart disease continues to place a massive burden on healthcare systems worldwide. According to global health organizations, cardiovascular disease kills millions of people every year and remains the number one cause of death in many countries. Any improvement in treatment could therefore have a major impact on public health.
The study also highlights how medical treatments continue to evolve. Many drugs once considered the “gold standard” are regularly re-evaluated as scientists collect better evidence and develop newer therapies.
Aspirin itself was once seen as one of the most important breakthroughs in heart disease prevention. Now researchers are asking whether even better options may exist.
Still, experts caution that treatment decisions should always be personalized. Some patients may benefit more from aspirin, while others may respond better to P2Y12 inhibitors. Factors such as age, bleeding risk, medical history, cost, and other medications all play a role in deciding the best treatment.
Patients are strongly advised not to stop aspirin or switch medications on their own without speaking to a doctor first. Blood-thinning medications must be carefully managed because stopping or changing them suddenly can increase the risk of serious complications.
The new findings offer hope for safer and more effective ways to prevent heart attacks and strokes in the future. As more research is completed, P2Y12 inhibitors may become a more common long-term treatment option for people living with heart disease.
The study represents another important step toward improving cardiovascular care and helping patients live longer, healthier lives.
If you care about heart health, please read studies about how eating eggs can help reduce heart disease risk, and Vitamin K2 could help reduce heart disease risk.
For more information about heart health, please see recent studies about how to remove plaques that cause heart attacks, and results showing a new way to prevent heart attacks, strokes.
Copyright © 2026 Knowridge Science Report. All rights reserved.
